Finance News – Eli Lilly
What is your interest today?
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
Weight-loss weariness and Trump threats wipe $250bn off Novo Nordisk and Eli Lilly
Concerns about pricing pressure and trade policies have led to a substantial decline in market value for companies specializing in obesity treatments, impacting investor confidence...
Read Full Article →Eli Lilly ramps up UK price of weight loss jab Mounjaro after Trump demands
Eli Lilly’s planned increase in the UK cost for its obesity medication reflects a strategic adjustment influenced by US political pressure, potentially affecting affordability and...
Read Full Article →Eli Lilly hikes UK price of blockbuster weight loss drug Mounjaro by up to 170%
The substantial increase in the cost of Mounjaro reflects a strategic pricing adjustment by Eli Lilly, which may influence overall expenditure within the UK pharmaceutical market d...
Read Full Article →Top Stock Movers Now: Tapestry, Deere, Eli Lilly, and More
Several major companies, including Tapestry, Deere, and Eli Lilly, experienced notable changes in their stock prices today, potentially impacting investor portfolios and market tre...
Read Full Article →Eli Lilly raises UK price of weight-loss drug Mounjaro by up to 170%
Eli Lilly has significantly increased the cost of its weight-loss medication in the UK, reflecting broader concerns about pricing disparities between countries and the financial bu...
Read Full Article →These Eli Lilly executives have been scooping up stock after its big drop
Following the disappointing trial results for the weight-loss medication, company leadership invested close to $3 million in shares, reflecting a notable financial commitment despi...
Read Full Article →Stocks Swing Lower as Eli Lilly, Fortinet Spiral: Stock Market Today
The decline in major stock indices reflects market concerns following several companies reporting earnings that fell short of investors’ expectations, impacting overall financial s...
Read Full Article →Eli Lilly’s weight-loss pill didn’t work so well, and the stock is tumbling
Eli Lilly experienced a decline in its share price after clinical trial results revealed limited effectiveness of its oral weight-loss medication, despite reporting strong earnings...
Read Full Article →TSX retreats from record high after earnings misses for consumer-related stocks
The Toronto Stock Exchange experienced a pullback following weaker-than-expected earnings from retail companies, while broader U.S. markets also declined amid disappointing pharmac...
Read Full Article →Trump's pharmaceutical tariffs could affect some drugmakers more than others
According to analyst Steve Scala, the impact of pharmaceutical tariffs may vary among companies, with AbbVie, Bristol Myers Squibb, and Eli Lilly potentially facing fewer challenge...
Read Full Article →Wegovy maker Novo Nordisk’s shares plunge as it cuts sales forecast
Novo Nordisk’s decision to lower its annual revenue and profit expectations has led to a significant drop in its stock value, reflecting investor concerns about the company’s compe...
Read Full Article →Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound
The success of a new obesity medication in China could challenge existing market leaders, potentially shifting investment dynamics within the pharmaceutical sector and impacting fu...
Read Full Article →Abbott jumps on RFK Jr. health push — plus, reviews of Eli Lilly's obesity drug data
Abbott’s recent involvement in supporting RFK Jr.’s health initiatives, along with the evaluation of Eli Lilly’s obesity medication findings, may influence market trends and invest...
Read Full Article →Weight loss drugs are blowing up the U.S. trade deficit. Trump is blaming Ireland
Recent substantial increases in pharmaceutical orders by companies like Eli Lilly have contributed to the widening U.S. trade deficit, reflecting efforts to navigate anticipated di...
Read Full Article →Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B
Eli Lilly's $1.3 billion acquisition of a gene-editing company has led to a notable increase in Verve Therapeutics' share value, reflecting investor optimism about potential financ...
Read Full Article →How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Despite its initial leadership in the growing weight loss medication sector, Novo Nordisk has recently experienced a decline in market share compared to Eli Lilly, affecting its fi...
Read Full Article →Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
Cigna’s Evernorth division reached an agreement that aims to reduce out-of-pocket expenses for employers and employees on certain weight management medications from Eli Lilly and N...
Read Full Article →Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Novo Nordisk’s leadership change aims to strengthen its position in the weight loss market, improve competitive standing against Eli Lilly, and address upcoming industry challenges...
Read Full Article →Eli Lilly stock sinks as pharma misses out on the market rally
Eli Lilly experienced a notable decline in share value as broader pharmaceutical stocks failed to benefit from the market’s upward movement, influenced by new government policies o...
Read Full Article →Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study
The superior results of Eli Lilly’s medication compared to Novo Nordisk’s in the recent trial may influence market dynamics and investor confidence within the competitive obesity t...
Read Full Article →Here’s how much extra weight is lost with Zepbound over Wegovy
A recent comparison of two popular weight-loss medications highlighted a measurable difference in effectiveness, potentially influencing market share and revenue for the companies...
Read Full Article →Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer...
Eli Lilly experienced a significant increase in sales attributed to strong demand for its weight loss and diabetes medications, yet adjusted its profit forecast following a recent...
Read Full Article →